Protagonist Therapeutics Inc (PTGX)
Working capital turnover
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 434,433 | 323,795 | 319,120 | 314,953 | 60,000 | 0 | 0 | 859 | 26,581 | 35,198 | 45,484 | 46,890 | 27,357 | 24,390 | 27,218 | 31,170 | 28,628 | 25,697 | 16,724 | 2,318 |
Total current assets | US$ in thousands | 591,641 | 476,769 | 570,925 | 627,553 | 355,577 | 324,881 | 316,941 | 235,736 | 237,355 | 276,617 | 304,302 | 341,522 | 340,736 | 327,687 | 371,818 | 285,508 | 315,606 | 204,151 | 217,466 | 125,986 |
Total current liabilities | US$ in thousands | 47,398 | 44,578 | 41,578 | 39,910 | 21,274 | 27,867 | 26,398 | 23,229 | 31,179 | 36,754 | 40,088 | 43,456 | 44,016 | 39,156 | 42,973 | 34,515 | 40,241 | 38,563 | 35,360 | 36,372 |
Working capital turnover | 0.80 | 0.75 | 0.60 | 0.54 | 0.18 | 0.00 | 0.00 | 0.00 | 0.13 | 0.15 | 0.17 | 0.16 | 0.09 | 0.08 | 0.08 | 0.12 | 0.10 | 0.16 | 0.09 | 0.03 |
December 31, 2024 calculation
Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $434,433K ÷ ($591,641K – $47,398K)
= 0.80
The working capital turnover ratio displays how efficiently a company is utilizing its working capital to generate revenues. A higher turnover ratio indicates better efficiency in using the working capital to generate sales.
In the case of Protagonist Therapeutics Inc, the working capital turnover ratio has fluctuated over the analyzed periods. From March 31, 2020, to December 31, 2021, the ratio experienced some volatility, ranging from as low as 0.03 to as high as 0.16. This variability suggests inefficiencies in managing the working capital during this period.
However, starting from March 31, 2022, the working capital turnover ratio began to stabilize and show an improvement in efficiency. The ratio steadily increased to 0.80 by December 31, 2024, indicating that the company has been utilizing its working capital more effectively to drive sales and revenue growth.
Overall, the trend in the working capital turnover ratio for Protagonist Therapeutics Inc shows a transition from periods of inefficiency to enhanced efficiency in recent years, reflecting improved management of working capital resources and potentially better operational performance.
Peer comparison
Dec 31, 2024